Abstract. Fangchinoline (FCL) is an active component isolated from the traditional medicinal plant Stephania tetrandra S. Moore, and has been reported to possess anti-cancer functions in several types of cancers; however, the effect of FCL on gastric cancer metastasis and its underlying molecular mechanisms remain unknown. The current study aimed to investigate the effect of FCL on the cell migration and invasion of human metastatic gastric cancer AGS cells and its mechanisms. Our study demonstrates that FCL dosage dependently suppressed the adhesion, migration and invasion capacities of human gastric cancer AGS cells without obvious cytotoxic effects. Reverse transcription-polymerase chain reaction and western blot assays demonstrated that FCL greatly inhibited the expression of matrix metalloproteinase (MMP)-2 and MMP-9 at both the mRNA and protein levels, while it significantly increased the expression of tissue inhibitor of metalloproteinase (TIMP) 1 and TIMP2 messenger RNAs. Our results also indicated that FCL repressed the phosphorylation of AKT in gastric cancer AGS cells. In summary, FCL may exert its anti-metastatic property in human gastric cancer cells in vitro by suppression of MMP-2 and MMP-9, increase of TIMP1 and TIMP2 genes, and inhibition of AKT phosphorylation. FCL may be a drug candidate for the treatment of gastric cancer metastasis.
Introduction
Gastric cancer is the fourth most common neoplasia and the second highest cause of mortality associated with cancer worldwide (1) . It is reported that gastric cancer is also the third most common type of cancer and the second highest cause of mortality in patients with cancer in China (1) . Complete excision of the gastric tumor is the best option of curative treatment (2) . In patients diagnosed at advanced stages, although chemotherapy effectively improves the survival quality and time, the median survival time of patients with advanced gastric cancer remains poor (1, 2) . The metastatic ability of gastric cancer is the leading cause of poor prognosis and high mortality (3) . Therefore, cancer metastasis is still a big challenge in the clinic for oncologists.
Accumulating data have demonstrated that degradation of extracellular matrix (ECM) proteins is the antecedent condition of malignant tumor metastasis (1) . Matrix metalloproteinases (MMPs) are part of the endopeptidase family and can cleave the majority of components of the ECM, including fibronectin, collagen, elastin, proteoglycan and laminin, thus playing critical roles in the development, progression and metastasis of malignant tumors (3, 4) . Upregulation of MMPs and altered expression of their tissue inhibitors [known as tissue inhibitors of metalloproteinases (TIMPs)] are associated with the invasiveness and metastasis of cancer cells (4) . Among them, MMP-2 and MMP-9 are the main enzymes for the degradation of basement membranes in cancer cells and/or stromal cells (4, 5) . TIMPs are natural inhibitors of MMPs, and TIMP2 specifically inhibits MMP-2, while TIMP1 inhibits MMP-9 (3).
Fangchinoline (FCL) is a bisbenzylisoquinoline alkaloid in Stephania tetrandra S. Moore (Fen fang ji) (6) . It is reported that FCL can inhibit histamine release (7), lower blood pressure as a non-specific calcium channel antagonist (8) and inhibit glutamate release from rat cortical synaptosomes (9) . In addition, FCL exerts anti-cancer activities in several types of malignant tumors, including breast cancer (10), prostate carcinoma (11), hepatocellular carcinoma (12) and lung cancer (13) . However, the effects of FCL on the metastasis of gastric cancer and its underlying mechanisms remain poorly understood.
In the present study, the anti-metastatic activity of FCL ( Fig. 1 ) in gastric cancer cells and its molecular mechanism of action were explored. Our data revealed that FCL inhibited the phosphorylation of AKT and upregulated TIMP2/1, leading to reduced expression of MMP-2/9 and inhibition of gastric cancer cell invasion in vitro.
antibodies against GAPDH (1:1,000, sc-25778), MMP-2 (1:500, sc-53630), MMP-9 (1:500, sc-21733), phosphorylated (p)-AKT (1:500, sc-135650) and AKT (1:500, sc-5298) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).
Cell culture. Human gastric cancer AGS cells (Type Culture
Collection of the Chinese Academy of Sciences, Shanghai, China) were cultured in high glucose-Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS; both HyClone; GE Healthcare Life Sciences, Chalfont, UK) and 200 mM glutamine at 37˚C under a humidified 95% air/5% CO 2 mixture (v/v).
Cell viability assay. Cells were seeded at a density of 5x10 3 cells/well in a 96-well microplate containing DMEM with 10% FBS, and incubated for 24 h. Next, cells were incubated with different concentrations of FCL for 24 h. The proliferation rate was determined with an MTT assay kit (Beyotime Institute of Biotechnology, Shanghai, China). The results were expressed as the absorbance at 570 nm, as previously reported (11) .
Cell adhesion assay. After pre-treating the cells with or without FCL (2, 4 and 8 µM) for 24 h, AGS cells were trypsinized and suspended at a final concentration of 2x10 5 cells/ml in serum-free medium. A total of 100 µl cell suspension was seeded to each well in a 96-well plate coated with 20 µg/ml fibronectin overnight. The cells were incubated for 30 min at 37˚C, and the non-adherent cells were removed by washing with PBS. MTT assay was used to determine the number of remaining adherent cells.
Wound healing assay. AGS cells were seeded on a 6-well plate and incubated in serum-free medium for 24 h. A transverse scratch wound on each monolayer of cells was created using a sterilized 200-µl pipette tip. The scratch wounded cell monolayers were then stimulated with various concentrations of FCL (0, 2, 4 and 8 µM) in 5% FBS for an additional 36 h, at which point, the cells that had migrated into the wound were photographed and analyzed.
Transwell chamber invasion assay. Transwell chamber invasion assay was conducted as described by Magee et al (14) . In brief, the transwell chambers (EMD Millipore, Billerica, MA, USA) were pre-coated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) for 1 h, and the upper chambers were washed using serum-free medium. Following incubation of AGS cells with FCL (0, 2, 4 and 8 µM) for 24 h, the cells were trypsinized and suspended at a density of 2x10 5 cells/ml in serum-free medium. A total of 200 µl cells were placed in the upper chambers, and medium with 10% FBS was placed in the lower chambers. After 24-h incubation at 37˚C, the non-invaded cells were removed using a cotton swab, while the invaded cells were fixed with 100% methanol and stained with hematoxylin and eosin (Nanjing Jiancheng Biotechnology Institute Co., Ltd., Nanjing, China). The invaded cells on the lower surface of the membrane filter were counted under an inverted microscope. The data are presented as the mean number of cells attached to the bottom surface from six randomly selected fields.
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from AGS cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Synthesis of complementary DNA was performed using the PrimeScript RT Reagent kit (Takara Biotechnology Co., Ltd., Dalian, China), and the PCR conditions were as follows: Initial denaturation at 95˚C for 5 min, followed by 24-33 cycles of denaturation at 94˚C for 30 sec, annealing at 54˚C for 30 sec and extension at 72˚C for 45 sec. The primer sequences were as follows: MMP-2 (forward 5'-TGG ATG ATG CCT TTG CTC GT-3' and reverse 5'-AAA CTT GCA GGG CTG TCC TT-3'); MMP-9 (forward 5'-GGA CAA GCT CTT CGG CTT CT-3' and reverse 5'-TTC AGG GCG AGG ACC ATA GA-3'); TIMP1 (forward 5'-CTC GTC ATC AGG GCC AAG TT-3' and reverse 5'-GTA GGT CTT GGT GAA GCC CC-3'); TIMP2 (forward 5'-TAG TGA TCA GGG CCA AAG CG-3' and reverse 5'-CAG GCT CTT CTT CTG GGT GG-3'); and GAPDH (forward 5'-GAG AAG GCT GGG GCT CAT TT-3' and reverse 5'-GTC AGG TCC ACC ACT GACAC-3'). The expression levels of MMP-2, MMP-9, TIMP1 and TIMP2 were normalized to those of GAPDH, which served as an internal control.
Western blot analysis.
To analyze the level of protein expression, cell lysates were prepared, as described previously (15), and separated by 10% SDS-PAGE and then transferred to polyvinylidene difluoride membranes for 2 h. The membrane was treated with blocking solution (5% bovine serum albumin in TBS) at room temperature for 1 h, and then incubated overnight at 4˚C with antibodies against MMP-2, MMP-9, AKT, p-AKT or GAPDH. The membranes were washed with Tris-buffered saline containing 0.5% Tween-20 (Beyotime Institute of Biotechnology), and then incubated for 1 h at room temperature with an anti-immunoglobulin G secondary antibody conjugated to horseradish peroxidase (1:1,000; A0208; Beyotime Institute of Biotechnology). The expression levels of the proteins were analyzed via chemiluminescence (Beyotime Institute of Biotechnology) and quantified using Quantity One software, version 4.6.2 (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The expression levels of MMP-2, MMP-9, p-AKT and AKT were normalized to those of the internal control GAPDH.
Statistical analysis. The results are expressed as the mean ± standard deviation from ≥3 independent experiments. The statistical differences between the experimental groups were assessed using a Student's t-test in SPSS version 13.0 (SPSS Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.
Results

FCL decreases cell proliferation in gastric cancer AGS cells.
To determine the inhibitory effect of FCL (Fig. 1A) on gastric cancer cell proliferation, an MTT assay was used. AGS cells were pre-treated with FCL (0-64 µM) for 24 h. As shown in Fig. 1B , gastric cancer cell proliferation was inhibited by FCL in a dose-dependent manner, while FCL at doses <8 µM exhibited little effect on the cell viability of gastric cancer AGS cells (Fig. 1B) . Therefore, these doses (0, 2, 4 and 8 µM) were used in the following experiments.
FCL inhibits the attachment of gastric cancer cells to fibronectin.
To determine the effect of FCL on cell adhesion to the ECM, an adhesion assay was conducted in gastric cancer AGS cells. As shown in Fig. 2 , FCL greatly inhibited cell adhesion ability in a dose-dependent manner, as demonstrated by cell attachment assay. Cell adhesion was inhibited by 41.53±4.85% for the 4-µM dose of FCL and by 85.63±3.51% for 8 µM FCL (Fig. 2) .
FCL reduces the migration of gastric cancer cells. Next, the inhibitory effect of FCL on cell migration was assessed in the artificial scratch wound of gastric cancer AGS cells. As shown in Fig. 3A , FCL obviously reduced cell numbers in the scratch wound area in gastric cancer AGS cells in a dose-dependent manner. The inhibitory rates of cell migration were 29.55±5.74, 64.65±4.99 and 76.68±4.82% for 2, 4 and 8 µM FCL, respectively (Fig. 3B) .
FCL suppresses cell invasion in gastric cancer cells.
A Boyden chamber assay was used to examine whether FCL could suppress the cell invasion of gastric cancer cells. As shown in Fig. 4A , exposure to FCL greatly decreased the invasive ability of gastric cancer cells in a concentration-dependent manner. The inhibitory rates of FCL on gastric cancer cells invasion were 13.47±7.30, 51.93±3.56 and 75.97±4.30% for 2, 4 and 8 µM FCL, respectively (Fig. 4B) .
Effects of FCL on the expression of MMP-2, MMP-9, TIMP2 and TIMP1 genes.
Accumulating evidence has demonstrated that MMPs, particularly MMP-2/MMP-9, and their inhibitors TIMP2/TIMP1 participated in the invasiveness and metastasis of malignant tumors via stimulating the degradation of ECM and cell migration (3, 5) . To verify the possible anti-metastatic molecular mechanism of FCL on gastric cancer cells, the expression of MMP-2/MMP-9 and TIMP2/TIMP1 genes was detected in FCL-treated gastric cancer AGS cells. The expression of MMP-2 and MMP-9 messenger (m) RNAs was obviously decreased in a concentration-dependent manner, with a maximum decrease of 31.23±4.16 and 63.83±4.64% for MMP-2 and MMP-9, respectively, following exposure to 8 µM FCL (Fig. 5) . In addition, the mRNA levels of their specific inhibitors TIMP2 and TIMP1 were significantly increased in a dose-dependent manner, with a maximum elevated rate of 1.96±0.08-fold and 1.50±0.06-fold for TIMP2 and TIMP1, respectively, upon exposure to 8 µM FCL (Fig. 5) . Additionally, the expression levels of MMP-2 and MMP-9 were also confirmed by western blot assay, and the results demonstrated that FCL also significantly inhibited the expression of MMP-2 and MMP-9 proteins in a similar pattern (Fig. 6) . The above data suggested that FCL inhibited the invasiveness of gastric cancer AGS cells via downregulation of MMP-2/MMP-9 and upregulation of TIMP2/TIMP1.
FCL reduces the phosphorylation of AKT in gastric cancer
cells. Since our data revealed that FCL exhibited inhibitory effects on cell adhesion, migration, invasion and proteinases, the effects of FCL on the expression of the components of the 
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phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/AKT pathway were explored by western blotting to elucidate the underlying molecular mechanisms. As shown in Fig. 6 , the phosphorylation of AKT was significantly reduced in a dose-dependent manner to 79.6±4.2 and 31.8±3.5% upon treatment with 4 and 8 µM FCL, respectively, while the total AKT levels were not significantly affected upon exposure to FCL. As an active compound of Stephania tetrandra S. Moore, FCL has been reported to exhibit anti-cancer effects, which are associated with cell apoptosis promotion, autophagic death induction, cell cycle arrest and multidrug resistance (6) (7) (8) ; however, the anti-metastatic activity of FCL has not been clarified yet, particularly in gastric cancer. The present study attempted to identify novel functions of FCL, and our data revealed that FCL inhibited cell adhesion, migration and invasion in human gastric cancer AGS cells without obvious cytotoxicity. In addition, the anti-metastatic function of FCL was associated with downregulation of MMP-2/9, upregulation of TIMP2/1 and decreased phosphorylation of AKT.
The invasion and metastasis of malignant tumors are the leading causes of poor prognosis in patients with gastric cancer, and these processes are usually accompanied by the destruction of basement membrane components in the ECM, which is mainly controlled by a number of proteolytic enzymes such as MMPs and their endogenous inhibitors TIMP2/1 (1, 5) . Immunohistochemistry analysis revealed that expression of MMP-2 and MMP-9 was detected in 94 and 70% of gastric cancer specimens, respectively, and it was associated with poor overall survival in patients with gastric cancer (16, 17) . Overexpression of MMP-2/9 was observed to accelerate the invasion of tumor cells in vitro and in vivo (18, 19) , and metastasis in MMP-2 and MMP-9-null mice was greatly suppressed compared with that in wild-type mice, suggesting that the elevated expression of MMP-2/9 promotes the metastatic potential of malignant tumor cells (3, 5) . Therefore, suppression of cancer migration and invasion mediated by MMP-2/9 provides a new direction for drug research in cancer metastasis. In the current study, exposure of human gastric cancer AGS cells to non-toxic doses of FCL inhibited cell adhesion, migration and invasion, compared with control cells, in a concentration-dependent manner. In addition, FCL was observed to inhibit the expression of MMP-2/9 mRNAs as well as their protein levels, while it increased the expression of TIMP2/1 genes, implying that FCL exhibited an ability to inhibit matrix degradation proteases, thus limiting the adhesive and invasive capabilities of gastric cancer cells.
A considerable number of studies have shown that PI3K/AKT signaling serves a critical role in regulating the expression of MMPs; therefore, suppression of PI3K/AKT signaling may inhibit proliferation, invasion, angiogenesis and metastasis in various malignant tumors (15) . In addition, inhibition of PI3K/AKT signaling could result in decreased expression of MMP-2/9 (20) (21) (22) . Considering that FCL at non-toxic doses (0-8 µM) could greatly suppress cell adhesion, migration and invasion via inhibition of MMP-2/9 mRNAs and proteins, the present authors hypothesized whether PI3K/AKT signaling was involved in this process. Our results demonstrated that FCL suppressed the phosphorylation of AKT in gastric cancer cells, suggesting that the inhibition of cell adhesion, migration and invasion by FCL could be mediated by suppression of MMP-2/9 and increase of TIMP2/1, in part, via decreasing the phosphorylation of AKT.
In summary, our current study has shown that FCL prevented the metastatic potential of human gastric cancer AGS cells via inhibition of MMP-2/9 and increase of TIMP2/1 through downregulation of PI3K/AKT signaling, thus highlighting the potential role of FCL in the therapy of gastric cancer metastasis.
